LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.
Questions? Call our customer API support number 1-(800)-881-8210
Latanoprost is a prostaglandin F2a analogue. Specifically, Latanoprost is a prostanoid selective FP receptor agonist that is believed to reduce the intraocular pressure (IOP) by increasing the outflow of aqueous humor. Thought of as a plumbing problem for the eye, Glaucoma is essentially when the drainage system of the eye is clogged. This clogging increases ocular pressure (IOP) and damages the optic nerve, leading to the diagnosis of glaucoma. If patients experience a prolonged period of time with elevated eye pressure they may have significant vision loss as a repercussion.
Latanoprost is an isopropyl ester prodrug which is inactive but which becomes active after hydrolysis to the acid from. Latanoprost opthalmic solution is a topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure. It is a prostaglandin analogue that works by increasing the outflow of aqueous fluid from the eyes.
Primarily hepatic (none except hydrolysis in the eye). Latanoprost is an isopropyl ester prodrug. It is hydrolyzed by esterases in the cornea to latanoprost acid, which is biologically active. The portion of the latanoprost acid that reaches the systemic circulation is metabolized primarily by the liver to 1, 2-dinor and 1, 2, 3, 4-tetranor metabolites by fatty acid beta-oxidation.
Between 5 and 15 percent of patients administered Latanoprost for six months or longer report at least one adverse effect from this drug. Common side effects reported include redness, blurry vision, burning, itching and stinging in the eye. Latanoprost may cause a long term change in the color of eyes, eyelids and eyelashes. These changes occur gradually and may be permanent.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.
Questions? Call our customer API support number 1-(800)-881-8210.